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In type 1 diabetes (T1D), the immune system 
destroys the insulin-producing  cells of the pan-
creas. The conventional treatment, consisting of 
life-long daily and multiple insulin injection only 
imperfectly  prevents  severe  hypoglycemia  and 
vascular complications. Thus, there is a clear 
need for improved treatments of T1D. At clini-
cal diabetes onset, residual  cells still produce 
insulin, offering a window for therapeutic inter-
vention to stop the autoimmune destruction and 
rescue  cell function. Extensive research and 
clinical studies are being developed in this direc-
tion (Chatenoud and Bluestone, 2007).
Even though the etiology and pathogenesis 
of human T1D are still poorly known, major 
paradigms of its physiopathology have been es-
tablished from studies in the nonobese diabetic 
(NOD) mice. We and others have shown that 
the CD4+CD25+Foxp3+ regulatory T cells (T reg 
cells) play a major role in the control of T1D 
(Salomon et al., 2000; Sakaguchi et al., 2006). 
Moreover, injecting islet-specific T reg cells can 
reverse established diabetes in NOD mice (Tang 
et al., 2004). However, at present the lack of 
good manufacture practice procedures to obtain 
antigen-specific T reg cells precludes the trans-
lation of such approach to the clinic. Stimulat-
ing the patient’s own T reg cell compartment to 
down-regulate the autoimmune process repre-
sents a more accessible alternative.
IL-2 was identified 30 yr ago for its strong   
capacity to stimulate T cells in vitro. Therefore,   
it has been used in the clinic for boosting the   
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Regulatory T cells (T reg cells) play a major role in controlling the pathogenic autoimmune 
process in type 1 diabetes (T1D). Interleukin 2 (IL-2), a cytokine which promotes T reg cell 
survival and function, may thus have therapeutic efficacy in T1D. We show that 5 d of  
low-dose IL-2 administration starting at the time of T1D onset can reverse established 
disease in NOD (nonobese diabetic) mice, with long-lasting effects. Low-dose IL-2 increases 
the number of T reg cells in the pancreas and induces expression of T reg cell–associated 
proteins including Foxp3, CD25, CTLA-4, ICOS (inducible T cell costimulator), and GITR 
(glucocorticoid-induced TNF receptor) in these cells. Treatment also suppresses interferon  
 production by pancreas-infiltrating T cells. Transcriptome analyses show that low-dose 
IL-2 exerts much greater influence on gene expression of T reg cells than effector T cells  
(T eff cells), suggesting that nonspecific activation of pathogenic T eff cells is less likely. 
We provide the first preclinical data showing that low-dose IL-2 can reverse established 
T1D, suggesting that this treatment merits evaluation in patients with T1D.
© 2010 Grinberg-Bleyer et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share  Alike  3.0  Unported  license,  as  described  at  http:// 
creativecommons.org/licenses/by-nc-sa/3.0/).
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et al., 2008). We and others also showed that young prediabetic 
NOD mice treated with low-dose IL-2 alone, or together with 
rapamycin, can be protected from the development of disease 
(Serreze et al., 1989; Rabinovitch et al., 2002; Tang, et al., 
2008). However, although >200 different treatments can pre-
vent T1D in NOD mice, only very few are effective to cure 
established disease (Shoda et al., 2005). In this paper, we show 
that only 5-d administration of low-dose IL-2 at diabetes onset 
can induce long-lasting remission in the treated animals. IL-2 
did not stimulate the diabetogenic effector T cells (T eff cells) 
but rather specifically stimulated CD4+Foxp3+ T reg cells in the 
pancreas to dampen the inflammatory milieu. Thus, in the pres-
ence of pathogenic T cells, IL-2 at a low dose is a selective T reg 
cell stimulator endowed with a great therapeutic potential.
RESULTS AND DISCUSSION
Short-term administration of low-dose IL-2 induces  
long-lasting diabetes remission in NOD mice but  
is inefficient in T reg cell–deficient mice
We assessed if 5 d of low-dose IL-2 administration could be   
effective to cure clinical diabetes in NOD mice. Remarkably, 
immune  response  in  certain  cancers  and  infectious  diseases 
(Zhang et al., 2005; Ahmadzadeh and Rosenberg, 2006).   
However, the results were often disappointing (Zhang et al., 
2005). The unexpected and severe T cell–mediated autoim-
mune syndrome of IL-2–deficient mice showed the complex 
role of this cytokine in the immune system (Sadlack et al., 1993). 
These findings were then explained by the critical role of IL-2 
on the peripheral survival and suppressive function of T reg cells 
(Papiernik et al., 1998). Consistent with this, IL-2 administration 
has been shown to expand and activate T reg cells in humans 
and mice (Zhang et al., 2005; Ahmadzadeh and Rosenberg, 
2006). Thus, although IL-2 has pleiotropic functions, its major 
impact is to favor T reg cell activity (Malek, 2008). Besides, 
NOD mice present a qualitative diminution of IL-2 production 
(Yamanouchi et al., 2007), and a genetic predisposing factor to 
T1D development in humans and NOD mice is linked to IL-2/
IL-2R gene polymorphisms (Vella et al., 2005).
We have recently reported that insufficient IL-2 amounts   
in the pancreas are responsible for poor T reg cell survival in   
this tissue, which could lead to progressive breakdown of self-
tolerance and development of diabetes in NOD mice (Tang   
Figure 1.  Diabetes remission by IL-2 therapy. (a and b) Spontaneous new-onset diabetic NOD mice (two consecutive blood glucose concentrations 
between 250 and 350 mg/dl) were treated for 5 d with PBS or denatured IL-2 (Ctrl), 25,000 IU IL-2 (IL-2), or 0.5 µg IL-2 + 5 µg anti–IL-2 (IL-2 complex). 
Blood glucose concentrations were monitored. (a) Percentage of diabetic mice. (b) Blood glucose concentrations in IL-2–treated (left) or control (right) mice. 
The 250 mg/dl blood glucose value is indicated by a dashed red line. Age at treatment onset was 26 ± 9.4 wk in mice that did not revert and 24 ± 7.6 wk in 
the cured ones. (c) Intraislet infiltration in IL-2–treated mice that remain free of overt diabetes 12–35 wk after treatment (IL-2 cured) and diabetes-free 
age-matched controls (healthy controls) was evaluated histologically. The graph shows the percentage of islets with no infiltration (0), peri-insulitis (1), 
moderate insulitis with <50% islet area infiltrated (2), and severe insulitis with >50% islet area infiltrated (3). Data for the control group represent 60 islets 
from four mice, and for the IL-2–treated group represent 22 islets from three mice. (d) Blood glucose concentrations in new onset diabetic mice that had 
not reverted after 5 d of IL-2 treatment and were further treated for 5 more days. Age at treatment onset was 22 ± 4.5 wk in mice that did not revert and 
22 ± 9.2 in the cured ones. * indicates a mouse that was sacrificed for analysis. (e and f) New onset diabetic CD28/ or WT littermate NOD mice were 
treated for 5 d with 25,000 IU IL-2 and blood glucose concentrations were monitored. (e) Percentage of diabetic mice. (f) Blood glucose concentrations.JEM VOL. 207, August 30, 2010  1873
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the different hematopoietic subpopulations potentially sensi-
tive to IL-2 in the spleen and pancreatic LN (PLN). Prediabetic 
(8–14 wk old) NOD mice were treated for 5 d with 25,000 IU 
(the low dose mentioned in the Introduction) or 250,000 IU 
IL-2. No significant change was observed at low-dose IL-2 on 
the total cell number, the proportion of CD4+, CD8+, 
CD4+Foxp3+, CD8+Foxp3+, NK, B, and CD11b+ cells   
(Table S1), or their activation status (unchanged CD44 expres-
sion; unpublished data). Also, the proportions of the different 
dendritic cell subpopulations remained unchanged (unpublished 
data). Only when high-dose IL-2 was used was cell homeostasis 
modified, with a significant increase of the cell numbers in PLN 
and the proportion of CD4+Foxp3+, CD4+CD25+Foxp3, and 
CD8+Foxp3+ populations in the spleen. These data indicated 
that 5 d of low-dose IL-2 administration did not modify steady-
state homeostasis of hematopoietic cells in lymphoid organs.   
In contrast, we have previously reported that low-dose admin-
istration of the IL-2/anti–IL-2 complex favored the expansion 
of T reg, T eff, NK, and CD8+ T cells in lymphoid tissues lead-
ing to a possible undesired systemic response (Tang et al., 2008). 
We thus focused on the mechanism of action of low-dose plain 
IL-2 for the rest of our study.
Low-dose IL-2 shows a profound and specific effect  
on pancreatic T reg cells
Data suggest that T reg cells present in the pancreas control the 
progression to destructive insulitis in prediabetic mice (Feuerer 
et al., 2009). However, under highly inflammatory conditions, 
reduced survival or insufficient function of T reg cells may   
unleash T eff cell autoimmune attack (Tang et al., 2008). To es-
tablish whether the IL-2 curative effect was related to a modifi-
cation of T reg cell numbers and/or characteristics in the 
pancreas, we quantified their proportion in the spleen, PLN, and 
pancreas of 8–9- and 15–16-wk-old prediabetic and new onset 
diabetic NOD mice. The proportion of T reg cells gradually in-
creased with age and disease evolution in the spleen, PLN, and 
islets (Fig. 2). Unexpectedly, in prediabetic mice (8–16 wk old), 
significantly lower proportions of T reg cells (8% of CD4+  
T cells) were found in the pancreas compared with normal ratios 
(10–15% of CD4+ T cells) in the spleen and PLN (Fig. 2 legend, 
this treatment induced diabetes remission in 60% of the mice 
within 1 wk, and most of them remained normoglycemic over 
the 10-wk duration of the experiment (Fig. 1, a and b). Five 
mice were followed up for 30–50 wk after treatment and were 
still diabetes free (unpublished data). Administration of an IL-2/
anti–IL-2 mAb complex, which induces a more dramatic T reg 
cell expansion than IL-2 alone (Tang et al., 2008), provided a 
similar but not better curative effect. Histological examination 
of mice that remained diabetes free for 12–35 wk after IL-2 
treatment showed that pancreatic islets were more infiltrated 
than  age-matched  nondiabetic  controls,  indicating  that  the 
treatment did not induce a long-lasting clearance of insulitis 
(Fig. 1 c). We tried to optimize treatment efficacy by prolong-
ing IL-2 administration or by combining IL-2 with drugs that 
are favorable for T reg cells, such as rapamycin, glucocorticoids, 
and -CD3 (Battaglia et al., 2005; Chen et al., 2006; Chatenoud 
and Bluestone, 2007). Prolonging IL-2 administration from 5 
to 10 d induced disease remission in three out of eight mice that 
had not reverted after 5 d (Fig. 1 d). The other treatments did 
no show obvious improved outcome (unpublished data).
Our previous results indicated that disease prevention by the 
IL-2/anti–IL-2 mAb complex was associated with increased   
T reg cell survival in the pancreas (Tang et al., 2008). To address 
the role of T reg cells in IL-2 remission of overt diabetes, we re-
peated the treatment in CD28 KO NOD mice, which have a 
profound deficit in T reg cells (Salomon et al., 2000). IL-2 ad-
ministration did not reverse hyperglycemia in CD28 KO mice, 
whereas diabetes remission was observed in two out of three 
WT littermates (Fig. 1, e and f), suggesting that low-dose IL-2 
therapy is inefficient in the absence of natural T reg cells. Over-
all, our results show, for the first time, that low-dose IL-2   
administration is one of the few treatments that can cure sponta-
neous overt diabetes in NOD mice (Shoda et al., 2005).
Short-term administration of low-dose IL-2 does not 
modify the peripheral homeostasis of hematopoietic cells
Given that T reg cells are not the only cells sensitive to IL-2 and 
that a systemic IL-2–mediated activation of T reg cells could 
lead to detrimental global immunosuppression, we performed a 
comprehensive analysis of the effect of IL-2 administration on 
Figure 2.  The proportion of T reg cells increases with age and disease in lymphoid tissues and in the pancreas of NOD mice. The percentage 
of Foxp3+ cells among CD4+ cells in the spleen, PLN, and pancreas of untreated nondiabetic NOD mice of different ages and recent onset diabetic NOD 
mice (new onset) was quantified by FACS. Graphs show cumulative individual and mean (horizontal bars) data from two to five independent experiments. 
Each symbol represents an individual mouse. *, P < 0.05; **, P < 0.001. The percentage of T reg cells in the pancreas at 8–9 wk is significantly different 
from the percentage of T reg cells in the PLN (P < 0.05) and spleen (P < 0.05) of mice of the same age. The percentage of T reg cells in the pancreas at  
15–16 wk is significantly different from the percentage of T reg cells in the PLN (P < 0.01) and spleen (P < 0.001) of mice of the same age.1874 IL-2 reverses established T1D | Grinberg-Bleyer et al.
Figure 3.  IL-2 treatment increases T reg cell proportions and reinforces the T reg cell phenotype specifically in inflamed pancreas. Prediabetic  
(a, c, and d) or new onset diabetic (e and f) NOD mice received five daily injections of PBS (Ctrl) or 25,000 IU IL-2 and were sacrificed 2 h after the last injection.  
(a and e) The percentage of Foxp3+ cells among CD4+ cells was determined by FACS in the spleen, PLN, and pancreas. Symbols represent individual mice and hori-
zontal bars are the means. (b) Percentage of Ki67+ cells among CD4+Foxp3+ cells from islets, PLN, and nondraining LN (NDLN) of prediabetic mice untreated (day 0) JEM VOL. 207, August 30, 2010  1875
Brief Definitive Report
p-values). At disease onset, the percentage of pancreatic T reg 
cell was significantly increased to reach 14% of CD4+ T cells.   
A similar increase in the proportion of T reg cell in PLN with 
aging has been reported (Mellanby et al., 2007). However, in 
this same study, T reg cell proportions were unchanged between 
nondiabetic and recent-onset diabetic mice, which is at odds 
with our results. This could be a result of variations between dif-
ferent NOD mice colonies or of the technique used to purify 
islet-infiltrating T cells. Our results confirm and complete our 
previous and paradoxical observation that T reg cells increase 
with age and disease development but not sufficiently to control 
autoimmunity (Tang et al., 2008). Also, we show for the first 
time that over time, consistently lower proportions of T reg cell 
are found in the pancreas compared with lymphoid tissues.
We then studied the IL-2 effect on the inflammatory pan-
creatic infiltrate of late prediabetic mice (14–19 wk old). After   
5 d of  low-dose IL-2 administration, the proportion of  T reg cells   
increased 1.7-fold in the pancreas of prediabetic mice, reaching 
similar proportions to those in the spleen and PLN, where T reg 
cell proportions were unchanged (Fig. 3 a). This increase was 
not associated with augmented T reg cell division, as the per-
centage of cycling cells, determined by the expression of Ki67 
(Fig. 3 b) and EdU incorporation (not depicted), was unaffected 
during IL-2 treatment. T reg cell division in LN was also unaf-
fected by IL-2 treatment (Fig. 3 b). We also verified that T eff 
cell cycling was not modified under IL-2 treatment (Fig. S1 a). 
The increase in the numbers of pancreatic T reg cells induced by 
IL-2 is most probably the result of an improvement of T reg cell 
survival (Tang et al., 2008) or, alternatively, of the conversion of 
T eff cells into induced T reg cells (Zheng et al., 2007), the re-
expression of Foxp3 in ex–T reg cells (Zhou et al., 2009), or the 
increased recruitment of T reg cells in the pancreas.
We also observed that IL-2 treatment was associated with 
a rise in the expression of molecules associated with T reg cell 
function such as CD25, Foxp3, CTLA-4 (CTL antigen 4), 
inducible T cell costimulator (ICOS), and glucocorticoid- 
induced TNF receptor (GITR; Fig. 3, c and d). Again, this 
effect was only noticed in pancreas-infiltrating T reg cells and 
not in T eff cells of the islets or PLN (Fig. S1 b).
Similar  analyses  were  repeated  in  new-onset  diabetic 
mice. In this case, in which high percentages of pancreatic   
T reg cells are already present before treatment, we did not ob-
serve a further increase in their numbers (Fig. 3 e). However, and   
as in prediabetic mice, IL-2 treatment induced a significant rise 
or treated with daily injections of 25,000 IU IL-2 for 3 or 5 d (days 3 and 5). n = 2–5 mice per group. The graph is representative of three independent experiments. 
(c and f) Mean fluorescence intensity (MFI) of CD25 and Foxp3 expression among CD4+Foxp3+ cells infiltrating the spleen, PLN, and pancreas, expressed as relative 
percentage from the mean fluorescence intensity value in the spleen, which has an arbitrary value of 100%. Graphs show cumulative mean data ± SEM from  
control mice (black) and mice treated with IL-2 for 5 d (white), from four to six independent experiments. *, P < 0.05; **, P < 0.001. A representative histogram of 
CD25 and Foxp3 intensities on CD4+ gated islet cells is shown for new onset diabetic animals (f, right). (d) Expression of the indicated molecules by CD4+Foxp3+ cells 
from mice treated with PBS (gray) or IL-2 (white) for 5 d. Graphs are representative of two to six independent experiments.
 
Figure 4.  IL-2 treatment induces a decrease in IFN- production by pancreas-infiltrating T cells. Cytokine production by CD4+ and CD8+ T cells from 
pancreas and PLN of NOD mice, treated as in Fig. 3, was quantified after ex vivo restimulation with PMA-ionomycin. (a) Percentage of CD4+ producing IL-10,  
IL-2, TNF, or IL-17 in control or IL-2–treated prediabetic NOD mice. Data cumulate two to three independent experiments. (b) Representative dot plot of IFN- 
production in CD4+ (top) and CD8+ (bottom) T cells in the pancreas of prediabetic mice treated or not with IL-2. Numbers in quadrants indicate percentage of 
cells. (c and d) Percentage of IFN-+ CD4+ (top) and CD8+ (bottom) T cells in islets and PLN of prediabetic (c) and new-onset diabetic (d) NOD mice. Data cumu-
late five and three experiments, respectively. Symbols represent individual mice and horizontal bars are the means. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.1876 IL-2 reverses established T1D | Grinberg-Bleyer et al.
of IL-2–treated animals and we could not detect TGF-  
under the same stimulation conditions (Fig. 4 a).
We then studied the production of TNF, IL-17, and IFN-, 
which are known to be toxic for  cells. TNF production by 
T cells, macrophages, and dendritic cells remained unchanged 
under IL-2 treatment (Fig. 4 a and not depicted) and similar 
small amounts of IL-17 were detected in control and IL-2–
treated mice (Fig. 4 a). Remarkably, IL-2 treatment induced 
an important reduction of IFN- production by both CD4+ 
and CD8+ pancreas-infiltrating T cells but no change in the 
PLN of prediabetic treated animals (Fig. 4, b and c).
Interestingly, when we repeated the experiment in new   
onset diabetic mice, IFN- production in IL-2–treated mice was 
also massively suppressed, specifically in pancreatic CD8+ T cells 
and to a lesser extent in PLN CD4+ T cells (Fig. 4 d). Consis-
tent with this, it has been shown that T reg cells limit IFN- 
production specifically in the pancreas, precluding the progres-
sion from nondestructive insulitis to diabetes (Feuerer et al., 
2009). Also, a similar reduction of intraislet IFN- production is 
associated with other treatments shown to prevent T1D devel-
opment in NOD mice, such as CFA, BCG, all-trans retinoic 
acid, and p277 peptide treatments (Ablamunits et al., 1998; 
Serreze et al., 2001; Van et al., 2009). These data suggest that 
one of the mechanisms of action of low-dose IL-2 is the limita-
tion of IFN- production by the pancreas-infiltrating T cells.
In vivo low-dose IL-2 treatment selectively modifies  
the T reg cell transcriptome, leaving the T eff cell gene 
profile practically unaltered
To have a global understanding of the mode of action of low-
dose IL-2 on T cells in vivo, we performed gene array analysis. 
in the expression of CD25 and Foxp3 in pancreatic T reg 
cells but not in lymphoid tissues (Fig. 3 f).
To evaluate if the specific effect of IL-2 on pancreatic   
T reg cells was unique to this nonlymphoid tissue, we studied 
the effect of IL-2 on T reg cells residing in other nonlymphoid 
sites, such as salivary glands, skin, colon, and liver. The per-
centage of T reg cells only significantly augmented after IL-2 
administration in the salivary glands (Fig. S2 a). However, 
IL-2 treatment induced the up-regulation of CD25 expression 
in all the assessed tissues and a minimal increase of Foxp3 ex-
pression in salivary glands and liver (Fig. S2 b).
The dual specificity achieved by the low-dose IL-2 treat-
ment is noteworthy. IL-2 effects are more marked in tissues 
with ongoing autoimmunity (pancreas and salivary glands) at 
the spatial level and to the T reg cells at the cellular level. This 
could be explained by the fact that there is a local deficit of 
IL-2, at least in the pancreas of NOD mice (Tang et al. 2008), 
and that exogenous low-dose IL-2 administration corrects 
this particular deficiency.
IL-2 treatment decreases IFN- production in the pancreas
IL-10, IL-2, and TGF- can contribute to the control of pan-
creatic inflammation (Rabinovitch et al., 2002; You et al., 
2007; Tang et al., 2008). Thus, we assessed the production of 
these cytokines by pancreas-infiltrating T cells after 5 d of IL-2 
or PBS treatment in prediabetic mice. The proportions of 
CD4+ and CD8+ T cell subsets among total CD45+ cells were 
similar in PBS- versus IL-2–treated animals (33 ± 13 vs. 31 ± 
15, n = 11, respectively for CD4+ T cells and 10 ± 5 vs. 9 ± 
7, n = 10, respectively for CD8+ T cells). IL-10 and IL-2 pro-
duction were not significantly increased in the CD4+ T cells 
Figure 5.  In vivo IL-2 treatment selectively modifies the T reg cell transcriptome. Gene array analysis was performed on FACS-sorted T eff cells and T reg 
cells from spleen and LN of Foxp3-GFP NOD mice treated with PBS or IL-2, as in Fig. 3. (Left) Venn diagram comparing the two gene lists (T eff cell–IL-2 vs. T eff cell–
PBS and T reg cell–IL-2 vs. T reg cell–PBS) filtered at twofold changes and with overlapping probes discarded. Probes are separated in up- or down-regulation by 
IL-2 from reference PBS. Genes modified by IL-2 only in T eff cells are in red, only in T reg cells are in green, and in both subsets are in blue. Each number represents 
the number of genes in each subgroup. (Right) Fc/Fc plot comparison of fold change expression values of IL-2 effect on T reg cells versus T eff cells for probes, with 
detection p-values <0.05. Only significant probes with fold change ≥2 are colored. Data are from one experiment with biological duplicates for each condition.JEM VOL. 207, August 30, 2010  1877
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IL-2 has been used in the clinic for >25 yr, constitute the first 
preclinical  data  indicating  that  low-dose  IL-2  can  control   
established autoimmunity and may place IL-2 as a safe thera-
peutic option for the treatment of pathologies with local and 
chronic inflammation.
MATERIALS AND METHODS
Mice. NOD mice were obtained from Charles River Laboratories or from 
our own colony. NOD Cd28/ (Lenschow et al., 1996) and NOD mice 
expressing  GFP  under  the  control  Foxp3  gene  promoter  (generated  by   
V. Kuchroo, Brigham and Women’s Hospital, Boston, MA) were maintained 
in our animal facility under specific pathogen-free conditions in agreement 
with current European legislation on animal care, housing, and scientific   
experimentation.  All  protocols  were  approved  by  The  Regional  Ethics 
Committee in Animal Experiment N°3 of Ile-de-France region.
IL-2 treatment. Mice were treated with daily i.p. injections of 25,000 IU 
of recombinant human IL-2 (Proleukin; Novartis), 250,000 IU IL-2, or 0.5 µg 
of recombinant mouse IL-2 and 5 µg of anti–IL-2 mAb complex for 5   
consecutive days. For Cd28/ mice, treatment was done during 10 d. De-
natured IL-2 was used as control. Glycosuria was measured using colorimet-
ric strips (Multistix; Bayer) and glycemia was quantified by a glucometer 
(Optium Xceed; Abbott Diabetes Care).
Spleen, LN, and tissue-infiltrating lymphocyte preparation. Spleen 
and LN were isolated and dissociated in PBS 3% FCS. For the other tissues 
and organs, mice were perfused with 0.9% NaCl, digested with collagenase/
DNase solution, and filtered, as previously described (Cassan et al., 2006). 
For pancreas and liver, a percoll density gradient step was performed as   
previously described (Baekkeskov et al., 1981).
Antibodies and flow cytometry analysis. Anti-CD4, anti-CD25, anti-
CD314 (NKG2D), anti-ICOS, anti-B220, anti-GITR, anti-CD44, anti–
CTLA-4, anti-CD11b, anti-CD11c, anti–IL-2, anti–IL-10, anti-TNF, 
anti–IL-17,  anti–IFN-,  and  anti-Ki67  labeled  with  PE,  allophycocyanin, 
PerCP, or Alexa Fluor 700, were purchased from BD. The PE- or Pacific blue–
labeled anti-Foxp3 staining was performed using a kit (eBioscience). In some 
cases, anti-Ki67 antibody (Ab) was added together with the anti-Foxp3 Ab. For 
intracellular cytokine staining, cells were restimulated with 1 µg/ml PMA 
(Sigma-Aldrich) and 0.5 µg/ml ionomycin (Sigma-Aldrich) for 4 h in the pres-
ence of 1 µl/ml GolgiPlug (BD). After cell surface staining, intracellular staining 
was performed using the Cytofix/Cytoperm kit (BD). Cells were acquired on 
an LSR II (BD) and analyzed with FlowJo (Tree Star, Inc.) software.
Histology. Pancreas were fixed in formol solution and processed for   
paraffin embedding. 5-µm-thick sections were stained with hematoxylin/
eosin and the degree of insulitis was evaluated microscopically.
Sample  generation  and  DNA  microarray  hybridization  and   
analysis. GFP-NOD mice were treated for 5 d with PBS or 25,000 IU   
IL-2 and sacrificed 2 h after the last injection. Untouched CD4+ T cells were 
enriched by magnetic cell separation (CD4+ T Cell Isolation kit; Miltenyi 
Biotec), labeled with CD4-PE Ab, and FACS sorted as CD4+GFP+ (T reg 
cells) and CD4+GFP (T eff cells). RNA was generated (RNeasy Mini   
kit; QIAGEN) from the sorted cells. RNA quality was verified in a Bioana-
lyzer (Agilent Technologies) and measured with a NanoDrop 1000 (Thermo 
Fisher Scientific).
Microarray experiments were performed on a MouseWG-6 BeadChip 
(Illumina), a genome-wide array with 45,282 probes. Data were extracted 
and Quantile normalized using BeadStudio software (Illumina). The working 
lists were created, filtering probes with detection p-values <0.05 for at least 
half of the chips involved in the comparison and discarding overlapping 
probes. Each dataset was derived from two biologically independent replicate 
samples. Independent samples were compared by computing fold ratios and 
filtered at twofold. The Microarray data accession no. is E-MEXP-2689.
We compared the transcriptome of highly purified T reg cells 
and T eff cells obtained from spleen and LNs of Foxp3-GFP 
NOD mice that received the same low-dose IL-2 treatment 
that cured new onset diabetic mice (T reg cell–IL-2 and T eff 
cell–IL-2) or PBS (T reg cell–PBS and T eff cell–PBS).
Analysis of genes with a fold change equal to or greater 
than two revealed that in T reg cells, IL-2 induced the over-
expression of 81 genes and down-regulation of 39 genes   
(Fig. 5, green). Surprisingly, only the expression of five genes 
(out of the 31,500 present in the gene chip) was modified 
in T eff cells. Four were also up-regulated in T reg cells 
(Socs2, IL2Ra, Serpina3g, and S100a8; Fig. 5, blue) and one 
was up-regulated only in T eff cells (Hist1h1c; Fig. 5, red). 
This result puts forward that nonspecific activation of patho-
genic T eff cells as a result of low-dose IL-2 administration is 
less likely.
The complete list of genes affected by IL-2 treatment in   
T reg cells is shown in Fig. S3. Globally, most of these 120 
genes do not have a direct relationship with the biology and 
suppressive function of T reg cells, which is in accordance with 
the absence of effect of IL-2 on peripheral T reg cells that we 
observed in our FACS analysis (Table S1 and Fig. 3). Only a 
few genes involved in T reg cell function and survival, such as 
IL-2Ra, Foxp3, Icos, and Bcl-2, were up-regulated by IL-2. 
This increased mRNA expression was only reflected by a   
minor,  but  nonstatistically  significant,  augmentation  of  the 
protein expression for CD25 and Foxp3 (Fig. 3 c) and no 
modification for ICOS protein expression (Fig. 3 d) in T reg 
cells of lymphoid tissues. Interestingly, the important rise in the 
expression level of these three proteins in pancreatic T reg cells 
(Fig. 3, c and d) could reflect an enhanced sensibility to IL-2 
caused by a local deficit of this cytokine in this tissue (Tang   
et al., 2008).
In conclusion, we show that a short course of low-dose 
IL-2 administration at diabetes onset can reverse established 
disease in NOD mice. This effect is long lasting and ineffi-
cient in the absence of naturally occurring T reg cells. The 
main mechanism seems to be an increased T reg cell activity   
in the pancreas. Drugs that boost the patients’ T reg cell com-
partment are under extensive investigation. This approach   
has been tested in a clinical trial using agonistic -CD28 
(Suntharalingam et al., 2006) and in preclinical models with 
high doses of IL-2, IL-2/–IL-2 complex, or Flt3-L (Swee   
et al., 2009). However, secondary effects caused by an action 
of these drugs on other cells, such as NK and T eff cells, have 
been observed and these drugs can lead to a systemic increase 
of T reg cells. As opposed to these treatments, low-dose IL-2 
appears to act specifically on T reg cells in inflamed nonlym-
phoid tissues, with no detectable effect on other cells, mini-
mizing the risk of generalized immune suppression. There is 
one ongoing clinical trial testing the use of IL-2 combined 
with  rapamycin  to  treat T1D  patients  (NCT00525889),  a 
combination which has been shown to prevent disease in 
mice (Rabinovitch et al., 2002), but neither IL-2 alone nor its 
association with rapamycin have ever been shown to cure   
established disease. Our findings, together with the fact that   1878 IL-2 reverses established T1D | Grinberg-Bleyer et al.
Statistical analyses. Statistical significances were calculated using the   
two-tailed unpaired Student t test with 95% confidence intervals.
Online supplemental material. Fig. S1 shows that T eff cell division and 
phenotype are not modified by low-dose IL-2 treatment. Fig. S2 provides infor-
mation on IL-2 effect on T reg cells in different nonlymphoid tissues. Fig. S3 
shows a heat map of IL-2 effect on T reg cell gene expression. Table S1 shows 
the systemic effects of low and high doses of IL-2. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20100209/DC1.
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